NDI-101150 Demonstrates Antitumor Activity, Safety in Heavily Pretreated RCC
NDI-101150 monotherapy demonstrated antitumor activity and was well tolerated among patients with heavily pretreated renal cell carcinoma.
Related Articles
PD-1 Inhibitors Make Impact in Merkel Cell Carcinoma, But Unmet Needs Persist
PD-1 Inhibitors have proved efficacious in approximately half of patients with metastatic MCC, and ongoing research in the field is looking at combination therapies.
NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer
Fruquintinib plus sintilimab injection has received conditional approval from the NMPA for mismatch repair–proficient advanced endometrial cancer.
RP1 and Other Oncolytic Viruses Could Pave a New Treatment Pathway in Advanced Melanoma
Bently P. Doonan, MD, discusses the utility of oncolytic viruses and the need for novel treatments after checkpoint inhibitors in advanced melanoma.
Oral Revumenib-Based Combo Produces Responses in R/R AML
Revumenib plus decitabine/cedazuridine and venetoclax produced responses in relapsed/refractory acute myeloid leukemia.
D-VRd Deepens MRD Responses in Transplant-Ineligible or -Deferred Newly Diagnosed Myeloma
Daratumumab plus VRd improved MRD responses and progression-free survival in transplant-ineligible or -deferred newly diagnosed multiple myeloma.
Revumenib Displays Activity in Relapsed/Refractory KMT2Ar Acute Leukemias
Revumenib demonstrated meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia.
Blinatumomab Plus Chemo Increases DFS Rates in Standard-Risk Pediatric B-ALL
Blinatumomab plus chemotherapy significantly improved 3-year DFS rates vs chemotherapy alone in pediatric patients with standard-risk pediatric B-ALL.
Dr Wang on Ziftomenib Plus Intensive Induction in Newly Diagnosed, NPM1+ or KMT2A+ AML
Eunice S. Wang, MD, on ziftomenib plus intensive induction in newly diagnosed, NPM1-mutated or KMT2A-rearranged acute myeloid leukemia.
FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan for EGFR+ NSCLC
Sacituzumab tirumotecan has received breakthrough therapy designation from the FDA for use in select patients with EGFR+ non–small cell lung cancer.